Shares of Nkarta, Inc. (NASDAQ:NKTX - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $11.20.
Several research firms have commented on NKTX. Weiss Ratings reissued a "sell (d-)" rating on shares of Nkarta in a report on Monday, September 21st. HC Wainwright initiated coverage on Nkarta in a report on Monday, November 2nd. They issued a "buy" rating on the stock. Wall Street Zen downgraded Nkarta from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. Needham & Company LLC reissued a "buy" rating on shares of Nkarta in a research note on Monday, November 9th. Finally, Stifel Nicolaus dropped their price target on Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, August 14th.
Read Our Latest Analysis on Nkarta
Institutional Trading of Nkarta
Hedge funds have recently modified their holdings of the company. Empowered Funds LLC grew its holdings in shares of Nkarta by 55.3% in the third quarter. Empowered Funds LLC now owns 108,165 shares of the company's stock valued at $283,000 after purchasing an additional 38,523 shares in the last quarter. StoneX Group Inc. purchased a new stake in Nkarta during the third quarter valued at $53,000. Samalin Investment Counsel LLC raised its stake in Nkarta by 68.5% during the third quarter. Samalin Investment Counsel LLC now owns 68,658 shares of the company's stock valued at $180,000 after purchasing an additional 27,908 shares in the last quarter. WINTON GROUP Ltd bought a new position in Nkarta during the second quarter valued at $45,000. Finally, Spark Investment Management LLC bought a new position in Nkarta during the second quarter valued at $33,000. 80.54% of the stock is owned by hedge funds and other institutional investors.
Nkarta Stock Performance
NKTX opened at $1.21 on Tuesday. The stock has a market capitalization of $86.76 million, a price-to-earnings ratio of -0.70 and a beta of 1.24. The company has a fifty day moving average of $2.17 and a 200 day moving average of $2.48. Nkarta has a fifty-two week low of $1.10 and a fifty-two week high of $3.72.
Nkarta (NASDAQ:NKTX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.05). On average, equities research analysts forecast that Nkarta will post -1.67 earnings per share for the current year.
Nkarta Company Profile
(
Get Free Report)
Nkarta, Inc. is a clinical-stage biotechnology company developing cell therapies based on natural killer (NK) cells, immune cells that can identify and attack abnormal cells. The company's approach uses donor-derived NK cells that are engineered to recognize cancer targets and intended for use as off-the-shelf treatments. Nkarta's research programs have included NKX019, an engineered NK-cell therapy targeting CD19, a protein found on certain B-cell cancers, and NKX101, designed to recognize stress signals on cancer cells.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nkarta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.
While Nkarta currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.